{"id":20554,"date":"2026-06-12T21:06:00","date_gmt":"2026-06-12T19:06:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=5ddd8deb0925fb1ce3cf64451c6e3e04"},"modified":"2026-06-12T21:06:00","modified_gmt":"2026-06-12T19:06:00","slug":"law-offices-of-frank-r-cruz-encourages-adma-biologics-inc-adma-shareholders-to-inquire-about-securities-fraud-class-action","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=20554","title":{"rendered":"Law Offices of Frank R. Cruz Encourages ADMA Biologics, Inc. (ADMA) Shareholders To Inquire About Securities Fraud Class Action"},"content":{"rendered":"

LOS ANGELES--(BUSINESS WIRE)--$STOCKS<\/a>--The Law Offices of Frank R. Cruz<\/a> announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired ADMA Biologics, Inc. (\u201cADMA\u201d or the \u201cCompany\u201d) (NASDAQ: ADMA<\/a>) securities between August 9, 2024 and March 25, 2026<\/b>, inclusive (the \u201cClass Period\u201d). ADMA investors have until August 10, 2026 <\/b>to file a lead plaintiff motion.<\/p>

IF YOU SUFFERED A LOSS ON YOUR ADMA BIOLOGICS, INC. (ADMA) INVESTMENTS, CLICK <\/b>HERE<\/b><\/a> TO SUBMIT A CLAIM TO POTENTIALLY RECOVER YOUR LOSSES IN THE ONGOING SECURITIES FRAUD LAWSUIT.<\/b><\/p>

You can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at info@frankcruzlaw.com<\/a>, by telephone at (310) 914-5007, or visit our website at www.frankcruzlaw.com<\/a>.<\/p><\/a><\/a>

What Happened?<\/b><\/p>

On March 24, 2026, Culper Research published a report alleging \u201cChannel Stuffing, an Undisclosed Related Party Distributor, and \u20133% Real Growth in 2025 vs. +20% Reported.\u201d Among other things, the report stated that \u201ctwo high-level employees at one of ADMA's two largest distributors,\u201d had confirmed independently that \u201cstarting in 2025, ADMA induced the distributor to stock excess ASCENIV by offering rebates and extended payment terms in order to meet order expectations. Distributors take unwanted product without having to pay for it, ADMA books the revenues, and reports growth that was never there<\/b>.\u201d<\/p>

On this news, ADMA\u2019s stock price fell $3.96, or 29.1%, over two consecutive trading days to close at $9.63 per share on March 25, 2026, thereby injuring investors.<\/p>

What Is The Lawsuit About?<\/b><\/p>

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and\/or misleading statements, as well as failed to disclose material adverse facts about the Company\u2019s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) ADMA engaged in an undisclosed related party transaction; (2) ADMA used channel stuffing to create an appearance of revenue; (3) ADMA lacked adequate internal controls; and (4) as a result, Defendants\u2019 positive statements about the Company\u2019s business, operations, and prospects were materially misleading and\/or lacked a reasonable basis at all relevant times.<\/p>

Contact Us To Participate or Learn More:<\/b><\/p>

If you purchased ADMA securities, wish to learn more about this action, or have any questions concerning this announcement or your rights or interests with respect to these matters, please click HERE<\/a> or contact us at:<\/p>

Law Offices of Frank R. Cruz2121 Avenue of the Stars, Suite 800Telephone: 310-914-5007Email: info@frankcruzlaw.com<\/a>Visit our website at: www.frankcruzlaw.com<\/a><\/p>

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/p> Contacts<\/b>

Law Offices of Frank R. Cruz2121 Avenue of the Stars, Suite 800Telephone: 310-914-5007Email: info@frankcruzlaw.com<\/a>Visit our website at: www.frankcruzlaw.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

LOS ANGELES–(BUSINESS WIRE)–$STOCKS–The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired ADMA Biologics, Inc. (\u201cADMA\u201d or the \u201cCompany\u201d) (NASDAQ: ADMA) sec…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-20554","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/20554","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20554"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/20554\/revisions"}],"predecessor-version":[{"id":20555,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/20554\/revisions\/20555"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20554"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20554"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20554"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}